Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device
The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail. We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced...
Gespeichert in:
Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2009-12, Vol.120 (23), p.2352-2357 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2357 |
---|---|
container_issue | 23 |
container_start_page | 2352 |
container_title | Circulation (New York, N.Y.) |
container_volume | 120 |
creator | RUSSELL, Stuart D ROGERS, Joseph G TODD MASSEY, H FARRAR, David J CONTE, John V MILANO, Carmelo A DYKE, David B PAGANI, Francis D ARANDA, Juan M KLODELL, Charles T BOYLE, Andrew J JOHN, Ranjit CHEN, Leway |
description | The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail.
We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37+/-14 to 23+/-10 mg/dL (P |
doi_str_mv | 10.1161/CIRCULATIONAHA.108.814863 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734175410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734175410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-2d9e7d2eb6c876f0cda96dee1b5c9374f652b22d925fe3fc20b09a5864bb159a3</originalsourceid><addsrcrecordid>eNpVkctu1DAUhi0EokPhFZBZIFaZ-prEyyhlmEjTi0oLy8hxTqhRxgm2M4hH4W1xNSMQqyMffZ-t3z9C7yhZU5rTi7q5qx921X1zc11tqzUl5bqkosz5M7SikolMSK6eoxUhRGUFZ-wMvQrhezrmvJAv0RlVinPFyxX6fQdOj1i7Hm9h1tEavFmciXZyuNnPfjoAtg5X_UE7A0-Q9hFvtB0XD_g2CeBiwJeLt-4bricXrVumJWSbcfqJPy_zPCX-q42POD7CUb_SEXDT4B0MEX9JvrdmGbXHVQg2RHwJB2vgNXox6DHAm9M8Rw-bj_f1NtvdfGrqapcZIUjMWK-g6Bl0uSmLfCCm1yrvAWgnjeKFGHLJOpYoJgfgg2GkI0rLMhddR6XS_Bx9ON6bwv5YIMR2b4OBcdQOUpC24IIWUlCSSHUkjZ9C8DC0s7d77X-1lLRPxbT_F5PWZXssJrlvT68s3R76f-apiQS8PwE6GD0OPv23DX85xhgXKi_4HySomnY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734175410</pqid></control><display><type>article</type><title>Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Journals@Ovid Complete</source><creator>RUSSELL, Stuart D ; ROGERS, Joseph G ; TODD MASSEY, H ; FARRAR, David J ; CONTE, John V ; MILANO, Carmelo A ; DYKE, David B ; PAGANI, Francis D ; ARANDA, Juan M ; KLODELL, Charles T ; BOYLE, Andrew J ; JOHN, Ranjit ; CHEN, Leway</creator><creatorcontrib>RUSSELL, Stuart D ; ROGERS, Joseph G ; TODD MASSEY, H ; FARRAR, David J ; CONTE, John V ; MILANO, Carmelo A ; DYKE, David B ; PAGANI, Francis D ; ARANDA, Juan M ; KLODELL, Charles T ; BOYLE, Andrew J ; JOHN, Ranjit ; CHEN, Leway ; HeartMate II Clinical Investigators</creatorcontrib><description>The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail.
We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37+/-14 to 23+/-10 mg/dL (P<0.0001) and from 1.8+/-0.4 to 1.4+/-0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121+/-206 and 171+/-348 to 36+/-19 and 31+/-22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1+/-0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9+/-0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device.
The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.108.814863</identifier><identifier>PMID: 19933938</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Female ; Glomerulonephritis ; Heart Failure - physiopathology ; Heart Failure - surgery ; Heart-Assist Devices ; Humans ; Kidney - physiology ; Liver - physiology ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Regional Blood Flow - physiology ; Ventricular Function, Left - physiology ; Young Adult</subject><ispartof>Circulation (New York, N.Y.), 2009-12, Vol.120 (23), p.2352-2357</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-2d9e7d2eb6c876f0cda96dee1b5c9374f652b22d925fe3fc20b09a5864bb159a3</citedby><cites>FETCH-LOGICAL-c440t-2d9e7d2eb6c876f0cda96dee1b5c9374f652b22d925fe3fc20b09a5864bb159a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22234967$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19933938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUSSELL, Stuart D</creatorcontrib><creatorcontrib>ROGERS, Joseph G</creatorcontrib><creatorcontrib>TODD MASSEY, H</creatorcontrib><creatorcontrib>FARRAR, David J</creatorcontrib><creatorcontrib>CONTE, John V</creatorcontrib><creatorcontrib>MILANO, Carmelo A</creatorcontrib><creatorcontrib>DYKE, David B</creatorcontrib><creatorcontrib>PAGANI, Francis D</creatorcontrib><creatorcontrib>ARANDA, Juan M</creatorcontrib><creatorcontrib>KLODELL, Charles T</creatorcontrib><creatorcontrib>BOYLE, Andrew J</creatorcontrib><creatorcontrib>JOHN, Ranjit</creatorcontrib><creatorcontrib>CHEN, Leway</creatorcontrib><creatorcontrib>HeartMate II Clinical Investigators</creatorcontrib><title>Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail.
We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37+/-14 to 23+/-10 mg/dL (P<0.0001) and from 1.8+/-0.4 to 1.4+/-0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121+/-206 and 171+/-348 to 36+/-19 and 31+/-22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1+/-0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9+/-0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device.
The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Female</subject><subject>Glomerulonephritis</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - surgery</subject><subject>Heart-Assist Devices</subject><subject>Humans</subject><subject>Kidney - physiology</subject><subject>Liver - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Regional Blood Flow - physiology</subject><subject>Ventricular Function, Left - physiology</subject><subject>Young Adult</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctu1DAUhi0EokPhFZBZIFaZ-prEyyhlmEjTi0oLy8hxTqhRxgm2M4hH4W1xNSMQqyMffZ-t3z9C7yhZU5rTi7q5qx921X1zc11tqzUl5bqkosz5M7SikolMSK6eoxUhRGUFZ-wMvQrhezrmvJAv0RlVinPFyxX6fQdOj1i7Hm9h1tEavFmciXZyuNnPfjoAtg5X_UE7A0-Q9hFvtB0XD_g2CeBiwJeLt-4bricXrVumJWSbcfqJPy_zPCX-q42POD7CUb_SEXDT4B0MEX9JvrdmGbXHVQg2RHwJB2vgNXox6DHAm9M8Rw-bj_f1NtvdfGrqapcZIUjMWK-g6Bl0uSmLfCCm1yrvAWgnjeKFGHLJOpYoJgfgg2GkI0rLMhddR6XS_Bx9ON6bwv5YIMR2b4OBcdQOUpC24IIWUlCSSHUkjZ9C8DC0s7d77X-1lLRPxbT_F5PWZXssJrlvT68s3R76f-apiQS8PwE6GD0OPv23DX85xhgXKi_4HySomnY</recordid><startdate>20091208</startdate><enddate>20091208</enddate><creator>RUSSELL, Stuart D</creator><creator>ROGERS, Joseph G</creator><creator>TODD MASSEY, H</creator><creator>FARRAR, David J</creator><creator>CONTE, John V</creator><creator>MILANO, Carmelo A</creator><creator>DYKE, David B</creator><creator>PAGANI, Francis D</creator><creator>ARANDA, Juan M</creator><creator>KLODELL, Charles T</creator><creator>BOYLE, Andrew J</creator><creator>JOHN, Ranjit</creator><creator>CHEN, Leway</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091208</creationdate><title>Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device</title><author>RUSSELL, Stuart D ; ROGERS, Joseph G ; TODD MASSEY, H ; FARRAR, David J ; CONTE, John V ; MILANO, Carmelo A ; DYKE, David B ; PAGANI, Francis D ; ARANDA, Juan M ; KLODELL, Charles T ; BOYLE, Andrew J ; JOHN, Ranjit ; CHEN, Leway</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-2d9e7d2eb6c876f0cda96dee1b5c9374f652b22d925fe3fc20b09a5864bb159a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Female</topic><topic>Glomerulonephritis</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - surgery</topic><topic>Heart-Assist Devices</topic><topic>Humans</topic><topic>Kidney - physiology</topic><topic>Liver - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Regional Blood Flow - physiology</topic><topic>Ventricular Function, Left - physiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUSSELL, Stuart D</creatorcontrib><creatorcontrib>ROGERS, Joseph G</creatorcontrib><creatorcontrib>TODD MASSEY, H</creatorcontrib><creatorcontrib>FARRAR, David J</creatorcontrib><creatorcontrib>CONTE, John V</creatorcontrib><creatorcontrib>MILANO, Carmelo A</creatorcontrib><creatorcontrib>DYKE, David B</creatorcontrib><creatorcontrib>PAGANI, Francis D</creatorcontrib><creatorcontrib>ARANDA, Juan M</creatorcontrib><creatorcontrib>KLODELL, Charles T</creatorcontrib><creatorcontrib>BOYLE, Andrew J</creatorcontrib><creatorcontrib>JOHN, Ranjit</creatorcontrib><creatorcontrib>CHEN, Leway</creatorcontrib><creatorcontrib>HeartMate II Clinical Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUSSELL, Stuart D</au><au>ROGERS, Joseph G</au><au>TODD MASSEY, H</au><au>FARRAR, David J</au><au>CONTE, John V</au><au>MILANO, Carmelo A</au><au>DYKE, David B</au><au>PAGANI, Francis D</au><au>ARANDA, Juan M</au><au>KLODELL, Charles T</au><au>BOYLE, Andrew J</au><au>JOHN, Ranjit</au><au>CHEN, Leway</au><aucorp>HeartMate II Clinical Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2009-12-08</date><risdate>2009</risdate><volume>120</volume><issue>23</issue><spage>2352</spage><epage>2357</epage><pages>2352-2357</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail.
We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37+/-14 to 23+/-10 mg/dL (P<0.0001) and from 1.8+/-0.4 to 1.4+/-0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121+/-206 and 171+/-348 to 36+/-19 and 31+/-22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1+/-0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9+/-0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device.
The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>19933938</pmid><doi>10.1161/CIRCULATIONAHA.108.814863</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 2009-12, Vol.120 (23), p.2352-2357 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_734175410 |
source | MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals; Journals@Ovid Complete |
subjects | Adolescent Adult Aged Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Glomerulonephritis Heart Failure - physiopathology Heart Failure - surgery Heart-Assist Devices Humans Kidney - physiology Liver - physiology Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Regional Blood Flow - physiology Ventricular Function, Left - physiology Young Adult |
title | Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A52%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renal%20and%20Hepatic%20Function%20Improve%20in%20Advanced%20Heart%20Failure%20Patients%20During%20Continuous-Flow%20Support%20With%20the%20HeartMate%20II%20Left%20Ventricular%20Assist%20Device&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=RUSSELL,%20Stuart%20D&rft.aucorp=HeartMate%20II%20Clinical%20Investigators&rft.date=2009-12-08&rft.volume=120&rft.issue=23&rft.spage=2352&rft.epage=2357&rft.pages=2352-2357&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIRCULATIONAHA.108.814863&rft_dat=%3Cproquest_cross%3E734175410%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734175410&rft_id=info:pmid/19933938&rfr_iscdi=true |